1. ALLA AKTIER
  2. NYHETER
  3. CHORDATE MEDICAL

Chordate Medical

Nyheter Chordate Medical Nyheter alla bolag

Chordate CEO Anders Weilandt explains study results at Aktiedagen on September 12th

On Monday, September 12th, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will mainly talk about the subgroup result of the migraine study PM007 on the K.O.S treatment that was presented in London on September 8, and what it means for the company. The subgroup result shows a statistically significant reduction in the number of headache days.

“This event will be a good opportunity for me to explain the very positive result from the subgroup analysis, how it should be interpreted and what it means for the company going forward”, says Anders Weilandt, Chordate CEO.

Aktiedagen takes place at Hotel Birger Jarl in Stockholm. To attend on site, register here. The event is streamed live at www.aktiespararna.se/tv/live and on Aktiespararna’s Youtube channel. No registration is required to follow the event digitally.

After the presentation, Anders Weilandt will participate in a Q&A and questions can be asked by sending an SMS to +46 79-347 98 45 or an email to event@aktiespararna.se. Questions can be sent in now or during the presentation.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in the Nordics, Germany, the UK, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com/en/

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Chordate CEO Anders Weilandt explains study results at Aktiedagen on September 12th

Datum 2022-09-08, kl 15:00
Källa MFN
Bifogade filer
Chordate CEO Anders Weilandt explains study results at Aktiedagen on September 12th
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!